SCHEMBL7674713

SCHEMBL7674713

CCCCCCC1C(=O)Oc2c(C)c(C(=O)c3ccc(C#N)cc3)n(C)c21

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM2 Q14416 4/20 0.39
CSNK2B P67870 2/20 0.34
CSNK2A1 P68400 2/20 0.34
MGLL Q99685 2/20 0.33
PIP5K1A Q99755 1/20 0.33
SLC6A3 Q01959 1/20 0.31
HSD17B10 Q99714 2/20 0.31
TSHR P16473 1/20 0.31
CA12 O43570 1/20 0.31
CA1 P00915 1/20 0.31
CA2 P00918 1/20 0.31
CA9 Q16790 1/20 0.31
HRH2 P25021 1/20 0.31
HRH1 P35367 1/20 0.31
CNR2 P34972 1/20 0.31
ALDH1A1 P00352 2/20 0.31
KDM4E B2RXH2 1/20 0.31
POLB P06746 1/20 0.31
HTT P42858 1/20 0.31
TP53 P04637 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7681373 0.92 ALDH1A1 (0.34) GRM2SLC6A3HSD17B10CA12CA1
SCHEMBL7676777 0.87 HTT (0.42) GRM2TSHRALDH1A1KDM4EPOLB
SCHEMBL7676758 0.87 NPSR1 (0.40) CNR2ALDH1A1KDM4EHTT
SCHEMBL7674520 0.81 ALDH1A1 (0.37) CA12CA1CA2CA9ALDH1A1
SCHEMBL7678168 0.81 PDE4B (0.39) MGLLTSHRALDH1A1GAA
SCHEMBL7677005 0.79 CHRM1 (0.36) GRM2HRH1CNR2ALDH1A1KDM4E
SCHEMBL7678014 0.71 ALDH1A1 (0.37) SLC6A3TSHRHRH1CNR2ALDH1A1
SCHEMBL7677930 0.69 ALDH1A1 (0.34) SLC6A3CA12CA1CA2CA9
SCHEMBL7682237 0.68 ALDH1A1 (0.40) ALDH1A1POLBHTTHPGDGAA
SCHEMBL7678696 0.66 ABCB11 (0.38) GRM2MGLLSLC6A3TSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6455703-B2 ADMINISTERING EFFECTIVE AMOUNT OF 1,3,6-TRIHYDRO-6-AZA-3-OXAPENTALEN-2-ONE DERIVATIVE TO THE PATIENT FOR INDUCING OR PROMOTING APOPTOSIS AND FOR ARRESTING UNCONTROLLED NEOPLASTIC CELL PROLIFERATION CELL PATHWAYS, INC. 2002-09-24 US disclosed
US-20010051651-A1 1,3,6,-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia OSI PHARMACEUTICALS, INC. 2001-12-13 US disclosed
US-6160003-A 1,3,6-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia CELL PATHWAYS, INC. (US) 2000-12-12 US disclosed
US-5939417-A 1,3,6-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia CELL PATHWAYS INC (US) 1999-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010051651-A1 1,3,6,-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia MALT1, VHL, CDKN1A GRM2 3896/4885CSNK2B 3208/4885CSNK2A1 2397/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.